软骨再生市场 - 全球产业规模、份额、趋势、机会及预测（按类型、治疗方式、应用、地区和竞争格局划分，2021-2031年）

全球软骨再生市场预计将从 2025 年的 17.5 亿美元成长到 2031 年的 45.7 亿美元，复合年增长率为 17.34%。

该市场涵盖细胞疗法、组织支架和生长因子等医疗解决方案，旨在修復受损的关节软骨。推动这一增长的关键因素包括全球骨关节炎负担的加重和运动创伤发生率的上升。此外，越来越多的患者倾向于选择关节保留疗法而非全关节置换术，这也支撑了对这些修復性治疗方法的需求。国际软骨再生与关节保护协会 (ICRPS) 的报告显示，其全球病患登记库的活跃参与者人数在 2024 年比前一年增长了 100% 以上，这体现了临床上日益增长的兴趣。

然而，报销方面的挑战严重阻碍了市场的广泛扩张。新型再生医学疗法的高昂费用往往无法获得公共或私人保险公司的全额报销，从而构成了准入门槛。这种支付模式的不确定性令医疗服务提供者望而却步，并限制了患者获得这些治疗方法，进而限制了新兴生物疗法的商业性扩充性。

市场驱动因素

全球老龄人口的成长以及由此导致的骨关节炎盛行率上升，正成为全球软骨再生市场发展的根本催化剂。随着人口老化的加剧，关节的累积机械磨损导致退化性疾病激增，使得人们迫切需要修復性干预措施，而非安宁疗护。这种人口结构的变化与患者对能够延缓或避免全置换术的生物製剂的需求成长直接相关。根据美国疾病管制与预防中心（CDC）于2024年1月发布的《骨关节炎》概况介绍，美国约有3,300万成年人患有骨关节炎。如此沉重的疾病负担凸显了开发有效再生药物以维持长期关节健康和活动能力的紧迫性。

同时，政府和私人对再生医学研究的投入不断增加，显着提升了该领域的技术能力。资金的涌入推动了先进组织工程计划和新型支架的研发，而这些项目和支架先前因高昂的研发成本而受阻。例如，在2024年9月题为「杜克大学获得高达3,300万美元联邦资金用于开发骨关节炎疗法」的新闻稿中，杜克大学健康中心宣布其研究团队已获得美国高级研究计划署（ARPA-H）的一项重大津贴，用于开发改良的关节再生解决方案。这项资金支持对于将基础研究转化为具有商业性价值的产品至关重要。儘管面临资金障碍，Vericel公司仍展现出巨大的市场潜力。该公司在2024年2月发布的「2023年第四季及全年财务表现」报告中指出，其软骨修復植入MACI的净销售额成长了25%，达到1.648亿美元。

市场挑战

新型再生医学技术的高成本，加上保险覆盖不足，严重阻碍了全球软骨再生市场的扩张。细胞疗法和组织支架等先进解决方案往往缺乏具体的报销代码，或被归类在模糊的支付模式，为医疗机构带来巨大的财务风险。这种不确定性使得医院和诊所不愿采用这些治疗方法，因为他们面临拒付和支付金额不足以支付生物製药高昂采购成本的风险。因此，患者主要只能自费接受治疗，这阻碍了这些治疗方法的商业性扩充性。

整形外科诊疗的经济负担进一步加剧了这个进入门槛。据美国整形外科医师学会称，美国医疗保险和医疗补助服务中心（CMS）将2024年医疗保险医师收费标准转换係数上年度降低了3.37%。整形外科服务标准报销额的降低削弱了支持昂贵创新疗法所需的财务空间。随着医疗机构收入来源的减少，将高成本的软骨再生技术纳入标准治疗方案的经济可行性降低，直接阻碍了市场成长。

市场趋势

微创关节关节镜植入系统的广泛应用正在从根本上改变市场格局，降低手术併发症风险，缩短患者復原时间。传统的开放式关节手术需要较大的切口和较长的住院时间，而先进的关节镜器械则可以透过微小的切口精准植入生物材料桥。这项技术进步，加上全球医疗模式向门诊治疗的转变，正促使复杂的软骨修復手术转移到日间手术中心进行。 2025年5月，Vericel在其「2025财年第一季财报」中宣布，其MACI植入季度销售额创下4,630万美元的历史新高。这一成长动能直接得益于该公司新推出的关节镜植入系统已成功培训了约400名外科医生。

同时，异体即用型细胞疗法的商业化正在克服自体移植手术的局限性，后者通常需要两次手术和较长的细胞培养期。这些即用型解决方案利用供体来源的细胞或易于取得的羊膜组织，无需进行切片检查采集，从而简化了供应链并显着降低了治疗成本。这种扩充性透过为骨关节炎和软骨缺损的治疗提供「即用型」替代方案，推动了医疗服务提供者的采用。为了满足这一市场需求，Organogenesis Holdings, Inc. 在 2025 年 11 月的「2025 财年第三季财报电话会议」上宣布，由于其产品系列在外科和运动医学领域的持续扩张和应用，公司净产品销售额达到 1.505 亿美元。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球软骨再生市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（纤维软骨、透明软骨、弹性软骨、其他）
  • 治疗方法（细胞疗法（软骨细胞、移植、生长因子技术）、非细胞疗法（组织支架、无细胞复合材料））
  • 依应用部位（膝盖、脊椎、脚踝、髋部等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美软骨再生市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲软骨再生市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区软骨再生市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲软骨再生市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美软骨再生市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球软骨再生市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Osiris Therapeutics, Inc
• Smith & Nephew Plc.
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.
• Medtronic Plc.
• Stryker Corporation
• Anika Therapeutics, Inc.
• B. Braun SE
• Orthocell Ltd.
• Geistlich Pharma AG
• Takeda Pharmaceutical Company Limited
• CONMED Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cartilage Regeneration Market is projected to expand from USD 1.75 Billion in 2025 to USD 4.57 Billion by 2031, reflecting a CAGR of 17.34%. This market comprises medical solutions such as cellular therapies, tissue scaffolds, and growth factors designed to repair damaged articular cartilage. Key drivers fueling this growth include the escalating global burden of osteoarthritis and the rising incidence of traumatic sports injuries. Additionally, a growing patient preference for joint preservation over total arthroplasty bolsters demand for these restorative interventions. Highlighting this increasing clinical interest, the International Cartilage Regeneration and Joint Preservation Society reported that active participation in its global patient registry rose by more than 100% in 2024 compared to the previous year.

However, broad market expansion is significantly impeded by reimbursement challenges. The high costs associated with novel regenerative procedures frequently lack adequate coverage from public and private insurance payers, establishing a financial barrier to entry. This ambiguity regarding payment models discourages healthcare providers and restricts patient access to these therapies, thereby limiting the commercial scalability of emerging biological solutions.

Market Driver

The growing global geriatric population and the associated prevalence of osteoarthritis act as fundamental catalysts for the Global Cartilage Regeneration Market. As the aging demographic increases, cumulative mechanical wear on articular joints leads to a surge in degenerative conditions, creating a critical need for restorative interventions rather than palliative care. This demographic shift correlates directly with rising patient demand for biological solutions capable of delaying or preventing total joint arthroplasty. According to the Centers for Disease Control and Prevention's 'Osteoarthritis' fact sheet from January 2024, approximately 33 million adults in the United States were estimated to have osteoarthritis, a substantial disease burden that underscores the urgency for effective regenerative therapies to maintain long-term joint health and mobility.

Concurrently, increased government and private funding for regenerative medicine research is significantly enhancing the sector's technological capabilities. Greater capital inflows facilitate the development of sophisticated tissue engineering projects and novel scaffolds that were previously hindered by high development costs. For instance, Duke Health announced in a September 2024 press release titled 'Duke Awarded Federal Funding up to $33 Million to Develop Osteoarthritis Therapies' that a research team secured a major grant from ARPA-H to create improved joint regeneration solutions. This financial support is pivotal for translating bench research into commercially viable products. Demonstrating the market's potential despite economic barriers, Vericel Corporation reported in its 'Fourth Quarter and Full-Year 2023 Financial Results' in February 2024 that net revenue for the MACI cartilage repair implant rose 25% to $164.8 million.

Market Challenge

The high cost of novel regenerative procedures, combined with inadequate insurance coverage, significantly hampers the expansion of the Global Cartilage Regeneration Market. Advanced solutions like cellular therapies and tissue scaffolds often lack specific reimbursement codes or fall into ambiguous payment models, creating substantial financial risk for healthcare providers. This uncertainty deters hospitals and clinics from adopting these therapies, as they face the risk of denied claims or insufficient payments that fail to cover the high acquisition costs of biological products. Consequently, patient access is restricted primarily to those capable of paying out-of-pocket, limiting the commercial scalability of these interventions.

The financial strain on orthopedic practices further exacerbates this barrier to entry. According to the American Association of Orthopaedic Surgeons, the Centers for Medicare & Medicaid Services implemented a 3.37% reduction in the Medicare Physician Fee Schedule conversion factor in 2024 compared to the prior year. This contraction in baseline reimbursement for orthopedic services erodes the economic margin necessary to support expensive, innovative treatments. As providers encounter tightening revenue streams, the financial viability of incorporating high-cost cartilage regeneration techniques into standard care pathways diminishes, directly stalling market growth.

Market Trends

The proliferation of Minimally Invasive Arthroscopic Delivery Systems is fundamentally reshaping the market by reducing surgical morbidity and accelerating patient recovery times. Unlike traditional open arthrotomy, which necessitates significant incisions and extended hospital stays, advanced arthroscopic instruments now enable the precise implantation of biologic scaffolds through portal-sized incisions. This technological evolution aligns with the global shift toward outpatient care, effectively moving complex cartilage restoration into ambulatory surgical centers. In May 2025, Vericel Corporation reported in its 'First Quarter 2025 Financial Results' record quarterly revenue for its MACI implant of $46.3 million, a growth trajectory directly supported by the successful training of approximately 400 surgeons on its newly launched arthroscopic delivery system.

Simultaneously, the Commercialization of Allogeneic Off-the-Shelf Cell Therapies is overcoming the logistical limitations of autologous procedures, which typically require two surgeries and extended cell culturing periods. By utilizing donor-derived cells or amniotic tissues available for immediate use, these off-the-shelf solutions eliminate the need for biopsy harvesting, thereby streamlining the supply chain and significantly reducing treatment costs. This scalability promotes provider adoption by offering a "ready-to-use" alternative for managing osteoarthritis and chondral defects. Validating this market demand, Organogenesis Holdings Inc. announced in its 'Third Quarter 2025 Earnings Call' in November 2025 that net product revenue reached $150.5 million, driven in part by the continued expansion and adoption of its surgical and sports medicine portfolio.

Key Market Players

• Osiris Therapeutics, Inc
• Smith & Nephew Plc.
• Vericel Corporation
• Zimmer Biomet Holdings, Inc.
• Medtronic Plc.
• Stryker Corporation
• Anika Therapeutics, Inc.
• B. Braun SE
• Orthocell Ltd.
• Geistlich Pharma AG
• Takeda Pharmaceutical Company Limited
• CONMED Corporation

Report Scope

In this report, the Global Cartilage Regeneration Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cartilage Regeneration Market, By Type

• Fibro Cartilage
• Hyaline Cartilage
• Elastic Cartilage
• Other

Cartilage Regeneration Market, By Treatment Modality

• Cell-Based (Chondrocyte, Transplantation, Growth Factor Technology)
• Non-Cell Based (Tissue Scaffolds, Cell-Free Composites)

Cartilage Regeneration Market, By Application

• Knee
• Spine
• Ankle
• Hip
• Others

Cartilage Regeneration Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cartilage Regeneration Market.

Available Customizations:

Global Cartilage Regeneration Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cartilage Regeneration Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Fibro Cartilage, Hyaline Cartilage, Elastic Cartilage, Other)
  • 5.2.2. By Treatment Modality (Cell-Based (Chondrocyte, Transplantation, Growth Factor Technology), Non-Cell Based (Tissue Scaffolds, Cell-Free Composites))
  • 5.2.3. By Application (Knee, Spine, Ankle, Hip, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cartilage Regeneration Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Modality
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cartilage Regeneration Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Modality
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Cartilage Regeneration Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Modality
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Cartilage Regeneration Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Modality
      • 6.3.3.2.3. By Application

7. Europe Cartilage Regeneration Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Modality
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cartilage Regeneration Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Modality
      • 7.3.1.2.3. By Application
  • 7.3.2. France Cartilage Regeneration Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Modality
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Cartilage Regeneration Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Modality
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Cartilage Regeneration Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Modality
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Cartilage Regeneration Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Modality
      • 7.3.5.2.3. By Application

8. Asia Pacific Cartilage Regeneration Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Modality
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cartilage Regeneration Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Modality
      • 8.3.1.2.3. By Application
  • 8.3.2. India Cartilage Regeneration Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Modality
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Cartilage Regeneration Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Modality
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Cartilage Regeneration Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Modality
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Cartilage Regeneration Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Modality
      • 8.3.5.2.3. By Application

9. Middle East & Africa Cartilage Regeneration Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Modality
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cartilage Regeneration Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Modality
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Cartilage Regeneration Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Modality
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Cartilage Regeneration Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Modality
      • 9.3.3.2.3. By Application

10. South America Cartilage Regeneration Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment Modality
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cartilage Regeneration Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Modality
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Cartilage Regeneration Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Modality
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Cartilage Regeneration Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Modality
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cartilage Regeneration Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Osiris Therapeutics, Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Smith & Nephew Plc.
• 15.3. Vericel Corporation
• 15.4. Zimmer Biomet Holdings, Inc.
• 15.5. Medtronic Plc.
• 15.6. Stryker Corporation
• 15.7. Anika Therapeutics, Inc.
• 15.8. B. Braun SE
• 15.9. Orthocell Ltd.
• 15.10. Geistlich Pharma AG
• 15.11. Takeda Pharmaceutical Company Limited
• 15.12. CONMED Corporation

16. Strategic Recommendations

17. About Us & Disclaimer